ArticleBMC cancer2025
Organ-specific cancer biomarker identification: a ten-year single-center study in southern China.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Leveraging extracellular vesicle biology for novel tests and therapeutics for kidney fibrosis.Clinical and translational medicine · 2026Review
- Artificial intelligence-based miRNA analysis for precision oncology: diagnostic and prognostic insights.Frontiers in molecular biosciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Cancer biomarker discovery is essential for early detection and monitoring, yet there is a lack of comprehensive studies examining organ-specific biomarkers across various cancer types. In this study, we analyzed clinical data from 59,184 cancer patients diagnosed between 2013 and 2023, focusing on 11 major cancer systems. We used propensity score matching with 55,010 healthy controls to create balanced comparison groups. Serum biomarker profiles were assessed through principal component analysis, differential expression analysis, and ROC curve analysis. Our findings revealed organ-specific biomarker patterns, such as decreased CA724, ferritin, and β2-microglobulin in thoracic cancer, reduced serum phosphorus in neurological cancer, and elevated cystatin C and creatinine in urinary system cancer. Further analysis across 22 cancer types uncovered additional biomarkers, including elevated ALT in hepatobiliary cancer, altered coagulation factors in laryngeal cancer, increased monocytes in pancreatic cancer, and reduced complement C3 in intestinal cancer. These results provide valuable insights into the unique biomarker signatures for different cancers, contributing to the potential development of more targeted and efficient screening methods.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.